P056  Recurrent ACE-inhibitor induced angioedema in a patient with long COVID-19 syndrome

Conclusion Bradykinin affects vascular permeability and results in vasodilatation, when patients take an ACE inhibitor there is a slower rate of bradykinin degradation and therefore this accumulation results in ACE inhibitor induced angioedema. SARS-CoV-2 binds to the ACE2 receptors. ACE2 is thought to coun terbalance ACE in the renin-angiotensin system, it is theorised that the potential downregulation of ACE2 by the presence of bound SARS-CoV-2 may therefore potentiate angioedema in susceptible individuals. At present we cannot confirm this proposed relationship and global current consensus supports the ongoing use of ACE inhibitors during the pandemic but clinicians should continue to be aware of emergent pathologies related to the COVID-19 pandemic.Disclosure H. Crawshaw: None.S. Webber: None.
Source: Rheumatology - Category: Rheumatology Source Type: research